BIRC2 and non-small cell lung carcinoma: Conversely, paclitaxel does not interfere with IAP-2 expression, and thus contributes efficiently to limit cell migration and subsequent metastatic potential, which accounts for the survival effect of RASSF1A promoter gene methylation in paclitaxel-treated NSCLC patients (Graphical abstract).